Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy

Area of Science:

• Immunology
• Cancer Biology
• Glycobiology

Background:

• Established tumors evade immune surveillance through mechanisms like altered cell surface carbohydrates, termed the 'tumor glycocode.'
• Tumor-associated glycans are promising biomarkers and therapeutic targets due to their consistent expression on cancer cells.
• Challenges in exploiting these glycans include low immunogenicity, immunosuppressive effects, and inefficient presentation via conventional MHC-restricted pathways.

Purpose of the Study:

• To review the role of tumor-associated glycans in anti-tumor immunity.
• To highlight the potential of gamma delta T cells (γδ T cells) in targeting the tumor glycocode.
• To explore novel therapeutic strategies based on the interaction between tumor glycans and γδ T cells.

Main Methods:

• Literature review focusing on tumor-associated glycans and γδ T cell interactions.
• Analysis of mechanisms by which tumors evade immune surveillance.
• Exploration of γδ T cell properties, including MHC-unrestricted antigen recognition.

Main Results:

• Tumor-associated glycans facilitate immune evasion by cancer cells.
• γδ T cells possess inherent anti-tumor properties and can recognize antigens independent of MHC.
• The interaction between tumor glycans and γδ T cells presents a potential avenue for cancer therapy.

Conclusions:

• Targeting the tumor glycocode with γδ T cells offers a promising strategy for novel cancer immunotherapies.
• Further understanding of this interaction could lead to innovative therapeutic interventions.
• Exploiting γδ T cells and tumor-associated glycans may overcome current limitations in cancer treatment.